Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

What Makes a Kinase Promiscuous for Inhibitors?

Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD, Seeliger MA.

Cell Chem Biol. 2018 Dec 11. pii: S2451-9456(18)30412-4. doi: 10.1016/j.chembiol.2018.11.005. [Epub ahead of print]

PMID:
30612951
2.

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.

Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN.

J Mol Biol. 2014 Jun 26;426(13):2457-70. doi: 10.1016/j.jmb.2014.04.014. Epub 2014 Apr 23.

3.

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G.

Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53. doi: 10.1016/j.ejphar.2008.10.014. Epub 2008 Oct 11.

PMID:
18938156
4.

Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.

Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL Jr, Levy RM.

J Med Chem. 2015 Jan 8;58(1):466-79. doi: 10.1021/jm501603h. Epub 2014 Dec 12.

5.

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, Gray NS.

ACS Chem Biol. 2013 Oct 18;8(10):2145-50. doi: 10.1021/cb400430t. Epub 2013 Aug 13. Erratum in: ACS Chem Biol. 2014 Mar 21;9(3):840.

6.

Type II Inhibitors Targeting CDK2.

Alexander LT, Möbitz H, Drueckes P, Savitsky P, Fedorov O, Elkins JM, Deane CM, Cowan-Jacob SW, Knapp S.

ACS Chem Biol. 2015 Sep 18;10(9):2116-25. doi: 10.1021/acschembio.5b00398. Epub 2015 Jul 20.

PMID:
26158339
7.

Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Kwarcinski FE, Brandvold KR, Phadke S, Beleh OM, Johnson TK, Meagher JL, Seeliger MA, Stuckey JA, Soellner MB.

ACS Chem Biol. 2016 May 20;11(5):1296-304. doi: 10.1021/acschembio.5b01018. Epub 2016 Mar 1.

PMID:
26895387
8.

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

Murray CW, Berdini V, Buck IM, Carr ME, Cleasby A, Coyle JE, Curry JE, Day JE, Day PJ, Hearn K, Iqbal A, Lee LY, Martins V, Mortenson PN, Munck JM, Page LW, Patel S, Roomans S, Smith K, Tamanini E, Saxty G.

ACS Med Chem Lett. 2015 Jun 4;6(7):798-803. doi: 10.1021/acsmedchemlett.5b00143. eCollection 2015 Jul 9.

12.
13.

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS.

ACS Chem Biol. 2014 Jun 20;9(6):1230-41. doi: 10.1021/cb500129t. Epub 2014 Apr 29. Review.

14.

Protein promiscuity: drug resistance and native functions--HIV-1 case.

Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.

J Biomol Struct Dyn. 2005 Jun;22(6):615-24.

PMID:
15842167
15.

From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.

Bethke E, Pinchuk B, Renn C, Witt L, Schlosser J, Peifer C.

ChemMedChem. 2016 Dec 16;11(24):2664-2674. doi: 10.1002/cmdc.201600494. Epub 2016 Nov 25.

PMID:
27885822
16.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.

Cancer Res. 2006 Jan 15;66(2):1007-14.

17.

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Cheetham GM, Charlton PA, Golec JM, Pollard JR.

Cancer Lett. 2007 Jun 28;251(2):323-9. Epub 2007 Jan 19.

PMID:
17240048
18.

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.

Roskoski R Jr.

Pharmacol Res. 2016 Jan;103:26-48. doi: 10.1016/j.phrs.2015.10.021. Epub 2015 Oct 31. Review.

PMID:
26529477
19.

DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.

Ung PM, Schlessinger A.

ACS Chem Biol. 2015 Jan 16;10(1):269-78. doi: 10.1021/cb500696t. Epub 2014 Dec 9.

20.

Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.

Zhao H, Huang D, Caflisch A.

ChemMedChem. 2012 Nov;7(11):1983-90. doi: 10.1002/cmdc.201200331. Epub 2012 Sep 13.

PMID:
22976951

Supplemental Content

Support Center